Changchun hi tech announced the annual report results, and the net profit increased by more than 60%

On January 3, Changchun hi tech released the 2019 performance forecast, which shows that in 2019, it is expected that the net profit attributable to the parent company of Changchun hi tech will be 1.61 billion yuan to 1.812 billion yuan, an increase of 60% to 80% year on year The main reasons for the year-on-year increase in net profit attributable to the company's shareholders in the reporting period include: 1 Income growth of holding backbone pharmaceutical enterprises; 2 The settlement income of real estate development projects increased year on year; 3 Major asset restructuring will be carried out in 2019 The company completed the acquisition of 29.5% minority shareholders' equity of Kinsey pharmaceutical in November 2019 Therefore, the company consolidated the financial statements of Kinsey pharmaceutical in November 2019 according to 99.5% shareholding ratio There are four core subsidiaries of Changchun hi tech, namely Changchun Jinsai Pharmaceutical Co., Ltd., Changchun Baike biology Co., Ltd., Changchun hi tech Real Estate Development Co., Ltd and Jilin Huakang Pharmaceutical Co., Ltd in the past few years, the company's net profit basically comes from Changchun Jinsai Jinsai pharmaceutical is mainly engaged in the R & D, production and sales of biological pharmaceutical products Its main products are recombinant human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-term water injection) and other recombinant human growth hormone products.